RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancer: major trial tests promising drug
Disease control OngoingThis study is testing whether a new drug called teclistamab works better than current standard treatments for people with multiple myeloma that has come back or stopped responding to prior therapy. It will involve about 614 adults whose cancer has progressed after 1 to 3 prior tr…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Drug maker tests new recipe for cancer treatment
Disease control OngoingThis study is checking if a new way of making the cancer drug teclistamab works the same in the body as the current method. It involves 108 people with multiple myeloma that has come back or stopped responding to other treatments. The main goal is to see if the drug levels in the…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New hope for multiple myeloma patients with no options left
Disease control APPROVED_FOR_MARKETINGThis program provides access to an investigational drug called talquetamab for people with multiple myeloma that has returned or stopped responding to all available treatments. Talquetamab is designed to help the body's own immune T-cells find and attack the cancer cells. It is o…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for Tough-to-Treat blood cancer: major trial tests promising drug combo
Disease control OngoingThis study is testing whether adding a new drug called mezigdomide to a standard two-drug therapy works better for people with multiple myeloma that has returned or stopped responding to treatment. About 525 participants who have had at least one prior treatment, including specif…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Last-Chance treatment offered for Tough-to-Treat blood cancer
Disease control NO_LONGER_AVAILABLEThis program provided early access to an investigational drug called talquetamab for patients with multiple myeloma that had stopped responding to standard treatments. It was designed for doctors to request the drug for individual patients who had exhausted other options. The pro…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New hope for Tough-to-Treat blood cancer: major trial tests promising drug combos
Disease control OngoingThis large Phase 3 study aims to find better treatments for multiple myeloma that has returned or stopped responding to previous therapies. Researchers are testing two new drug combinations against the current standard treatment in 864 participants. The main goal is to see which …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC